



Living Cell Technologies Limited

ACN: 104 028 042

ASX: LCT

OTCQB: LVCLY

ASX ANNOUNCEMENT

Change of Address

Sydney, Australia & Auckland, New Zealand – 28 February 2022 – Living Cell Technologies (ASX: LCT) advises that the registered office address and principal place of business address for LCT will change to from our previous address in Melbourne to Sydney, effective immediately.

The new address is as follows:

Level 16, Tower 2, Darling Park
201 Sussex Street
Sydney NSW 2000

LCT Executive Chairman, Professor Bernie Tuch said: "This move will simplify our operational structure and facilitate progress with our NTCELL research and other key projects to advance shareholder value."

The company maintains an office in Auckland, New Zealand also, reflecting its longstanding history and shareholder support in New Zealand.

Authorised for release by the Chair of Living Cell Technologies Limited.

– Ends –

For further information: www.lctglobal.com

<p>At the Company: Bernie Tuch Chief Executive Mobile: +61 411 461 604 bernietuch@lctglobal.com</p>	<p>For media queries: Anthony Fensom Republic PR Mobile: +61 407 112 623 anthony@republicpr.com.au</p>
--	--

About Living Cell Technologies

Living Cell Technologies Limited (ASX:LCT) is an Australasian biotechnology company that is focused on discovering and developing novel treatments for debilitating conditions such as diabetes and Parkinson's disease.

LCT is listed on the Australian (ASX: LCT) and US (OTCQB: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in Australia and New Zealand.

For more information visit www.lctglobal.com or follow @lctglobal on Twitter, Facebook or LinkedIn.